AV-412
- Generic Name
- AV-412
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44ClFN6O7S2
- CAS Number
- 451493-31-5
- Unique Ingredient Identifier
- Z541VW0W40
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00551850
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Kansas Masonic Cancer Research Center, Kansas City, Kansas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00381654
- Locations
- 🇦🇷
Hospital Universitatrio Austral, Buenos Aires, Argentina
🇦🇷Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath